Phuong K Morrow

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Hot flashes: a review of pathophysiology and treatment modalities
    Phuong Khanh H Morrow
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:1658-64. 2011
  2. ncbi Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy
    Phuong K Morrow
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe, Box 1354, Houston, TX 77030, USA
    Breast Cancer Res Treat 123:837-42. 2010
  3. ncbi Effects of chronic hepatitis C infection on the treatment of breast cancer patients
    P K H Morrow
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 21:1233-6. 2010
  4. ncbi Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
    Phuong Khanh H Morrow
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 11:207. 2009
  5. ncbi Effect of CYP2D6 polymorphisms on breast cancer recurrence
    Phuong K Morrow
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1221-7. 2012
  6. ncbi Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy
    Phuong K Morrow
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77005, USA
    J Clin Oncol 29:3126-32. 2011
  7. ncbi Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype
    Rachel L Theriault
    Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 11:325-31. 2011
  8. ncbi Pregnancy after the diagnosis of breast cancer
    Phuong Khanh H Morrow
    Department of Cancer Medicine, M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:173-5. 2006
  9. ncbi Management of breast cancer in the genome era
    Phuong Khanh H Morrow
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Annu Rev Med 60:153-65. 2009
  10. ncbi New biological agents in the treatment of advanced non-small cell lung cancer
    Phuong Khanh H Morrow
    Departments of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4095, USA
    Semin Respir Crit Care Med 26:323-32. 2005

Detail Information

Publications10

  1. ncbi Hot flashes: a review of pathophysiology and treatment modalities
    Phuong Khanh H Morrow
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:1658-64. 2011
    ..Hormonal therapies, including estrogens and progestogens, are the most well-known and efficient agents in alleviating hot flashes; however, the safety of these agents is disputable...
  2. ncbi Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy
    Phuong K Morrow
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe, Box 1354, Houston, TX 77030, USA
    Breast Cancer Res Treat 123:837-42. 2010
    ..5%) and fatigue (44.6%). There were no deaths related to the study drug. Sagopilone was moderately tolerated in both treatment arms and showed limited activity in heavily pre-treated patients with MBC...
  3. ncbi Effects of chronic hepatitis C infection on the treatment of breast cancer patients
    P K H Morrow
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 21:1233-6. 2010
    ..Although hepatitis C (HCV) is the most common blood-borne infection in the United States, little information exists about treatment of breast cancer in the setting of chronic HCV...
  4. ncbi Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
    Phuong Khanh H Morrow
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 11:207. 2009
    ....
  5. ncbi Effect of CYP2D6 polymorphisms on breast cancer recurrence
    Phuong K Morrow
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1221-7. 2012
    ....
  6. ncbi Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy
    Phuong K Morrow
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77005, USA
    J Clin Oncol 29:3126-32. 2011
    ..Our trial evaluated the safety and efficacy of the combination of everolimus and trastuzumab in women with HER2-overexpressing metastatic breast cancer (MBC) that progressed on trastuzumab-based therapy...
  7. ncbi Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype
    Rachel L Theriault
    Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 11:325-31. 2011
    ..This article evaluates the risk of recurrence for patients who have small node-negative breast cancer by age and tumor subtype...
  8. ncbi Pregnancy after the diagnosis of breast cancer
    Phuong Khanh H Morrow
    Department of Cancer Medicine, M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:173-5. 2006
  9. ncbi Management of breast cancer in the genome era
    Phuong Khanh H Morrow
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Annu Rev Med 60:153-65. 2009
    ..Epigenetics is being evaluated for its ability to influence estrogen receptor expression. However, these fields require further validation. This review discusses the advances in the management of breast cancer through genomic evaluation...
  10. ncbi New biological agents in the treatment of advanced non-small cell lung cancer
    Phuong Khanh H Morrow
    Departments of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4095, USA
    Semin Respir Crit Care Med 26:323-32. 2005
    ..As the number of therapeutic agents increases in NSCLC, there will be greater emphasis on the selection of an appropriate patient population in which to give specific, targeted therapies...